Please wait while the formulary information is being retrieved.
Drug overview for BESIVANCE (besifloxacin hcl):
Generic name: BESIFLOXACIN HCL (BE-si-FLOX-a-sin)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Besifloxacin is a fluoroquinolone anti-infective agent.
No enhanced Uses information available for this drug.
Generic name: BESIFLOXACIN HCL (BE-si-FLOX-a-sin)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Besifloxacin is a fluoroquinolone anti-infective agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for BESIVANCE (besifloxacin hcl) have been approved by the FDA:
Indications:
Bacterial conjunctivitis
Professional Synonyms:
Inflammation of the conjunctiva due to bacteria
Indications:
Bacterial conjunctivitis
Professional Synonyms:
Inflammation of the conjunctiva due to bacteria
The following dosing information is available for BESIVANCE (besifloxacin hcl):
Besifloxacin is commercially available for topical ophthalmic administration as besifloxacin hydrochloride; dosage is expressed in terms of besifloxacin.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BESIVANCE 0.6% SUSP | Maintenance | Adults instill 1 drop into affected eye(s) by ophthalmic route 3 times per day at intervals of 4 to 12 hours for 7 days |
No generic dosing information available.
The following drug interaction information is available for BESIVANCE (besifloxacin hcl):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for BESIVANCE (besifloxacin hcl):
Drug contraindication overview.
The manufacturer states that there are no known contraindications to besifloxacin 0.6% ophthalmic suspension.
The manufacturer states that there are no known contraindications to besifloxacin 0.6% ophthalmic suspension.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| No disease contraindications |
The following adverse reaction information is available for BESIVANCE (besifloxacin hcl):
Adverse reaction overview.
Conjunctival redness.
Conjunctival redness.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Ocular pain |
| Rare/Very Rare |
|---|
| None. |
There are 5 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Conjunctival hyperemia |
Blurred vision Headache disorder Ocular irritation Ocular itching |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for BESIVANCE (besifloxacin hcl):
Safety and efficacy of besifloxacin 0.6% ophthalmic suspension have not been established in children younger than 1 year of age. Although systemic quinolones have been associated with arthropathy in immature animals, there is no evidence that ophthalmic administration of quinolones has any effect on weight bearing joints.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.) Data are not available regarding use of besifloxacin 0.6% ophthalmic suspension in pregnant women. In animal studies using oral besifloxacin dosages up to 1 g/kg daily, there was no evidence of visceral or skeletal malformations in offspring, but this dosage was associated with maternal toxicity and mortality, increased postimplantation loss, decreased fetal body weights, and decreased fetal ossification.
Although besifloxacin has not been measured in human milk, the manufacturer states that it is presumed that the drug is distributed into human milk. Caution is advised if besifloxacin ophthalmic suspension is used in nursing women.
No overall differences in safety and efficacy of besifloxacin 0.6% ophthalmic suspension have been observed between geriatric and younger adults.
The following prioritized warning is available for BESIVANCE (besifloxacin hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for BESIVANCE (besifloxacin hcl)'s list of indications:
| Bacterial conjunctivitis | |
| H10.02 | Other mucopurulent conjunctivitis |
| H10.021 | Other mucopurulent conjunctivitis, right eye |
| H10.022 | Other mucopurulent conjunctivitis, left eye |
| H10.023 | Other mucopurulent conjunctivitis, bilateral |
| H10.029 | Other mucopurulent conjunctivitis, unspecified eye |
| H10.3 | Unspecified acute conjunctivitis |
| H10.30 | Unspecified acute conjunctivitis, unspecified eye |
| H10.31 | Unspecified acute conjunctivitis, right eye |
| H10.32 | Unspecified acute conjunctivitis, left eye |
| H10.33 | Unspecified acute conjunctivitis, bilateral |
Formulary Reference Tool